Moderna (MRNA) Change in Receivables (2018 - 2026)
Moderna (MRNA) posted quarterly Change in Receivables of -$53.0 million for Q2 2026, down 76.67% year-over-year from -$227.1 million in Q2 2025, and up 53.51% on a QoQ basis from -$114.0 million in Q1 2026.
Moderna (MRNA) Change in Receivables (2018 - 2026) Analysis & Trends
Moderna has reported Change in Receivables for 9 years, with the latest figure at -$53.0 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at -$53.0 million, down 76.67% year-over-year; the trailing twelve-month figure through Jun 2026 was -$13.0 million (up 88.7% YoY), and the FY2025 annual result was -$156.0 million, up 70.79% from the prior year.
- Change in Receivables improved to -$53.0 million in Q2 2026, from -$114.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $1.6 billion in Q3 2023 and troughed at -$1.3 billion in Q4 2022.
- A 5-year average of -$174.4 million and a median of -$193.0 million in 2023 frame the typical range for Change in Receivables.
- The largest YoY upside for Change in Receivables was 40750.0% in 2023 against a maximum downside of 27100.0% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$1.3 billion in 2022, then gained by 25.65% to -$974.0 million in 2023, then dropped by 23.82% to -$1.2 billion in 2024, then advanced by 28.77% to -$859.0 million in 2025, then soared by 93.83% to -$53.0 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$53.0 million in Q2 2026, -$114.0 million in Q1 2026, and -$859.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.00 Mn |
| Jun 30, 2026 | -53.00 Mn |
| Mar 31, 2026 | -114.00 Mn |
| Mar 31, 2026 | -114.00 Mn |
| Dec 31, 2025 | -859.00 Mn |
| Dec 31, 2025 | -859.00 Mn |
| Sep 30, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | -30.00 Mn |
| Jun 30, 2025 | -30.00 Mn |
| Mar 31, 2025 | -280.00 Mn |
| Mar 31, 2025 | -280.00 Mn |
| Dec 31, 2024 | -1.21 Bn |
| Dec 31, 2024 | -1.21 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 26.00 Mn |
| Mar 31, 2024 | -755.00 Mn |
| Mar 31, 2024 | -755.00 Mn |